Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The current standard treatment for throat cancer that is positive for the human papillomavirus (HPV) is 7 weeks of daily radiation therapy given together with chemotherapy, but this treatment can have severe side effects. In this study, researchers are assessing significantly lower doses of radiation (3 weeks) to achieve local and regional control of the tumor with significantly fewer side effects. Treatments will be given in combination with lower doses of chemotherapy (cisplatin, carboplatin, and 5-fluorouracil) as well in people with HPV-positive throat cancer.
Normally when people have B-cell lymphoma that is not in complete remission, they do not immediately have another treatment. They have observation. That means their doctor closely monitors their disease with imaging tests to see if their disease is improving or worsening. If their disease gets worse, they may receive more treatment.
Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.
Brentuximab vedotin (BV) plus chemotherapy with the drugs cyclophosphamide, doxorubicin, and prednisone (CHP) is a standard treatment for T-cell lymphomas that make the CD30 protein. Researchers want to see if BV with an enhanced chemotherapy regimen that includes etoposide works better in people with T-cell lymphomas.
Nadofaragene firadenovec is a gene therapy that delivers a copy of a protein called IFNa2b to your kidney. This may help your immune system find and destroy cancer cells. By killing the cancer cells, nadofaragene firadenovec may cause your cancer to stop growing and spreading.
Researchers want to see if it is practical to give immunotherapy before kidney cancer surgery. The people in this study have no evidence of cancer spread in other parts of their body. Researchers also want to see if this treatment causes any delays in surgery. Immunotherapy is treatment that boosts the body's natural defenses to fight cancer.
Researchers want to find the best dose of TNG456 to use alone or with abemaciclib to treat brain cancer. The people in this study have glioblastoma that has spread. In addition, their cancer is missing a protein called MTAP.
Mirdametinib blocks proteins called MEK1 and MEK2, which play an important role in cancer cell growth and survival. By blocking MEK1 and MEK2, mirdametinib may slow or stop the growth of your cancer.
Researchers want to see how well revumenib works against acute leukemia. The people in this study have acute leukemia that keeps growing after treatment. They also have a mutation (change) in the HOX gene, which is related to new or immature leukemia cells.
In addition, their cancers have a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive NSCLC.
